Crinetics Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Checking your notes…
(in thousands)
| Common Stock | CommonStock andPaid-In | AccumulatedOtherComprehensive | Accumulated | TotalStockholders’ | |
|---|---|---|---|---|---|
| Shares | Capital | Income (Loss) | Deficit | Equity | |
| Balance at January 1, 2022 | 47,597 | $607,581 | $(382) | $(275,255) | $331,944 |
| Issuance of common stock, net of $7,758 transaction costs | 5,626 | 117,242 | — | — | 117,242 |
| Vesting of shares subject to repurchase | 1 | 2 | — | — | 2 |
| Exercise of stock options | 524 | 4,721 | — | — | 4,721 |
| Stock issued under Employee Stock Purchase Plan | 129 | 1,618 | — | — | 1,618 |
| Stock-based compensation | — | 28,268 | — | — | 28,268 |
| Comprehensive loss | — | — | (3,549) | — | (3,549) |
| Net loss | — | — | — | (163,918) | (163,918) |
| Balance at December 31, 2022 | 53,877 | 759,432 | (3,931) | (439,173) | 316,328 |
| Issuance of common stock, net of $22,735 of transaction costs | 12,787 | 369,080 | — | — | 369,080 |
| Issuance of common stock upon vesting of restricted stock units | 81 | — | — | — | — |
| Exercise of stock options | 1,283 | 20,091 | — | — | 20,091 |
| Stock issued under Employee Stock Purchase Plan | 147 | 2,291 | — | — | 2,291 |
| Stock-based compensation | — | 40,937 | — | — | 40,937 |
| Comprehensive income | — | — | 4,908 | — | 4,908 |
| Net loss | — | — | — | (214,529) | (214,529) |
| Balance at December 31, 2023 | 68,175 | 1,191,831 | 977 | (653,702) | 539,106 |
| Issuance of common stock, net of $49,442 of transaction costs | 21,986 | 970,048 | — | — | 970,048 |
| Issuance of common stock upon vesting of restricted stock units | 249 | — | — | — | — |
| Exercise of stock options | 2,294 | 40,463 | — | — | 40,463 |
| Stock issued under Employee Stock Purchase Plan | 222 | 4,224 | — | — | 4,224 |
| Stock-based compensation | — | 69,386 | — | — | 69,386 |
| Comprehensive loss | — | — | (14) | — | (14) |
| Net loss | — | — | — | (298,408) | (298,408) |
| Balance at December 31, 2024 | 92,926 | $2,275,952 | $963 | $(952,110) | $1,324,805 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.